Format

Send to

Choose Destination
Diabetes Obes Metab. 2018 Jul;20(7):1793-1797. doi: 10.1111/dom.13268. Epub 2018 Mar 22.

Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial.

Kantartzis K1,2,3, Fritsche L1,2,3, Bombrich M1, Machann J2,3,4, Schick F2,3,4, Staiger H1,2,3, Kunz I5, Schoop R5, Lehn-Stefan A1,2,3, Heni M1,2,3, Peter A1,2,3, Fritsche A1,2,3, Häring HU1,2,3, Stefan N1,2,3.

Author information

1
Department of Internal Medicine IV, Division of Endocrinology, Diabetology, Vascular Medicine, Nephrology and Clinical Chemistry, University of Tübingen, Tübingen, Germany.
2
Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Centre Munich at the University of Tübingen, Tübingen, Germany.
3
German Center for Diabetes Research (DZD), Tübingen, Germany.
4
Department of Radiology, Section on Experimental Radiology, University of Tübingen, Tübingen, Germany.
5
DSM Nutritional Products, Kaiseraugst, Ltd, Kaiseraugst, Switzerland.

Abstract

We performed the largest randomized, placebo-controlled clinical trial to date (N = 112, 12-week intervention) to investigate the effects and safety of resveratrol supplementation on liver fat content and cardiometabolic risk parameters in overweight and obese and insulin-resistant subjects. At baseline the variability in liver fat content was very large, ranging from 0.09% to 37.55% (median, 7.12%; interquartile range, 3.85%-12.94%). Mean (SD) liver fat content was 9.22 (6.85) % in the placebo group and 9.91 (7.76) % in the resveratrol group. During the study liver fat content decreased in the placebo group (-0.7%) but not in the resveratrol group (-0.03%) (differences between groups: P = .018 for the intention-to-treat [ITT] population; N = 54, resveratrol, N = 54, placebo and P = .0077 for the per protocol [PP] population). No effects of resveratrol supplementation on cardiometabolic risk parameters were observed. Resveratrol supplementation was well tolerated and safe. In conclusion, these data suggest that resveratrol supplementation is safe and that it does not considerably impact liver fat content or cardiometabolic risk parameters in humans.

KEYWORDS:

NAFLD; clinical trial; fatty liver; insulin resistance; resveratrol

PMID:
29484808
DOI:
10.1111/dom.13268
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center